Stock comparison
Harmony Biosciences Holdings
West Pharmaceutical Services
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
WST
West Pharmaceutical Services
Market cap
$22.35B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | WST | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 58C | HRMY |
| Benjamin Graham | 60C | 88A | WST |
| Philip Fisher | 75B | 47D | HRMY |
| Peter Lynch | 62C | 24F | HRMY |
| Joel Greenblatt | 28F | 60C | WST |
| Charlie Munger | 62C | 60C | HRMY |
| Terry Smith | 67B | 54C | HRMY |
Side-by-side metrics
| Metric | HRMY | WST |
|---|---|---|
| Market cap | $1.75B | $22.35B |
| P/E (TTM) | 11.8x | 39.8x |
| EV/EBIT | 6.4x | 34.0x |
| ROIC (TTM) | 12.5% | 15.24% |
| Gross margin | 76.55% | 36.24% |
| Net margin | 16.2% | 16.85% |
| Revenue CAGR 5y | 29.85% | 2.08% |
| EPS CAGR 5y | 46.45% | -6.4% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 0.29% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EPS CAGR 5y46.45%vs -6.4%+114%
- Revenue CAGR 5y29.85%vs 2.08%+93%
- EV/EBIT6.4xvs 34.0x+81%
- P/E (TTM)11.8xvs 39.8x+70%
WST leads on
- Dividend yield0.29%vs 0.0%+100%
- Market cap$22.35Bvs $1.75B+92%
- Debt / Equity0.1xvs 0.2x+53%
- ROIC (TTM)15.24%vs 12.5%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.